A Phase 1, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs Rucaparib (Primary) ; Caffeine; Digoxin; Midazolam; Omeprazole; Vitamin K; Warfarin
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Acronyms DDI
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 24 Mar 2018 Results evaluating the effect of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib on the pharmacokinetics (PK) of selected substrates of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein (P-gp) presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 06 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 31 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top